K-pop

Mixed-gender group KARD to make a comeback on the 28th with their first full-length album

"Where to Now? Part: Now Here" Released Follow-up to the 7th mini-album released in 2024

KIM HYUNSIK
2026-07-02 08:50:26
[Edaily Starin KIM HYUNSIK Reporter] The mixed-gender group KARD (BM, J.Seop, Jeon So-min, Jeon Ji-woo) is making a comeback with a full-length album.
(Photo courtesy of DSP Media)
According to their agency, DSP Media, on the 2nd, KARD will release their first full-length album, “Where To Now? Part.2: NOWHERE,” on the 28th.
This album serves as a follow-up to KARD’s seventh mini-album, “Where To Now? Part.1: Yellow Light,” released in August 2024.
On that day, KARD caught fans’ attention by releasing a teaser image on their official social media channels, showing a poster with details about their comeback album placed on asphalt scattered with colorful confetti.
An agency representative explained, “With this, their first full-length album since debut, KARD will conclude the ‘Where To Now?’ series, which posed the question ‘Where are we headed?’ and set a new musical milestone.”
Meanwhile, ahead of their comeback, KARD will hold a concert in Tokyo, Japan, on the 4th as part of their world tour “DRIFT.”

Economy

Corporation

IT·Science

Economy

Following Shinhan and Kookmin, Hana Has Also Been Hacked… Data on 89 Customers, Including Resident Registration Numbers, Leaked

Personal information leaks are occurring simultaneously across the banking sector due to attacks by hackers. A view of Hana Bank’s headquarters. (Photo courtesy of Hana Bank) Hana Bank announced…
2026-10-02 18:08:37

Corporation

GI Innovation and G2G Bio Jump 20% on Hopes for a Licensing Deal [K-bio pulse]

The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
2026-10-03 07:22:03

IT·Science

Yoon Tae-young, CEO of OSCOTEC Inc.: “The Era of Fast Followers Is Over… We’ll Compete with Innovative New Drugs”

“The approach of chasing targets that have already been validated by others no longer suits the Korean biotech industry.”Yoon Tae-young, CEO of OSCOTEC Inc., made this remark during a separate intervi…
2026-10-02 18:24:02